Risk of Malignant Transformation of Giant Cell Tumors of Bone Is 8 Times Lower with Megavoltage vs. Orthovoltage Radiation Therapy.

Q2 Medicine
Sarcoma Pub Date : 2022-10-21 eCollection Date: 2022-01-01 DOI:10.1155/2022/7216296
Farah N Musharbash, Alexander Edelstein, Jad M El Abiad, Adam S Levin, Sara R Alcorn, Carol D Morris
{"title":"Risk of Malignant Transformation of Giant Cell Tumors of Bone Is 8 Times Lower with Megavoltage vs. Orthovoltage Radiation Therapy.","authors":"Farah N Musharbash, Alexander Edelstein, Jad M El Abiad, Adam S Levin, Sara R Alcorn, Carol D Morris","doi":"10.1155/2022/7216296","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The first-line treatment for most giant cell tumors (GCTs) of bone is surgical; radiotherapy (RT) is reserved for inoperable or refractory cases. While RT techniques have undergone a dramatic change over the past few decades, with the higher energy megavoltage RT replacing orthovoltage RT, concerns for high rates of malignant transformation following RT have limited its use. Evidence suggests a lower incidence of secondary malignancy after treatment with megavoltage compared with orthovoltage RT, but this has not been studied in GCTs. Our main purpose was to compare the incidence of malignant transformation of GCTB between patients treated with orthovoltage vs. megavoltage RT.</p><p><strong>Methods: </strong>A literature review was performed to identify studies reporting GCTBs treated with RT from 01/1900 through 12/2019. Studies that did not report RT modality or separate orthovoltage and megavoltage results were excluded. Included in the analysis were 6 patients from our institution. Primary outcome was the incidence of malignant transformation; secondary outcomes were time to transformation and incidence of local recurrence. Fisher's exact tests and independent sample <i>t</i>-tests were used, and significance was set at <i>p</i> < 0.05.</p><p><strong>Results: </strong>Twenty-two studies were included, which reported on 168 GCTBs treated with orthovoltage and 393 treated with megavoltage RT. Transformation incidence was 14% (<i>n</i> = 24) for orthovoltage and 1.8% (<i>n</i> = 7) for megavoltage RT, an 8-fold difference (odds ratio (OR) 9.1, 95% confidence interval (CI) 3.9-22, <i>p</i> < 0.001). Mean time to transformation was 8.7 years for orthovoltage and 11.2 years for megavoltage RT (<i>p</i>=0.28). Incidence of local recurrence was 38% (63/167) for orthovoltage and 17% (66/393) for megavoltage RT (OR 3.3, 95% CI 2.0-4.6, <i>p</i> < 0.001).</p><p><strong>Conclusions: </strong>The risk of developing a malignancy after RT of GCTB is 8 times lower with megavoltage than with orthovoltage. Malignant transformation with megavoltage, while not zero, is lower than that in historical series. Use of modern RT techniques in inoperable or refractory GCTB may be appropriate.</p>","PeriodicalId":21431,"journal":{"name":"Sarcoma","volume":" ","pages":"7216296"},"PeriodicalIF":0.0000,"publicationDate":"2022-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9616653/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Sarcoma","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2022/7216296","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The first-line treatment for most giant cell tumors (GCTs) of bone is surgical; radiotherapy (RT) is reserved for inoperable or refractory cases. While RT techniques have undergone a dramatic change over the past few decades, with the higher energy megavoltage RT replacing orthovoltage RT, concerns for high rates of malignant transformation following RT have limited its use. Evidence suggests a lower incidence of secondary malignancy after treatment with megavoltage compared with orthovoltage RT, but this has not been studied in GCTs. Our main purpose was to compare the incidence of malignant transformation of GCTB between patients treated with orthovoltage vs. megavoltage RT.

Methods: A literature review was performed to identify studies reporting GCTBs treated with RT from 01/1900 through 12/2019. Studies that did not report RT modality or separate orthovoltage and megavoltage results were excluded. Included in the analysis were 6 patients from our institution. Primary outcome was the incidence of malignant transformation; secondary outcomes were time to transformation and incidence of local recurrence. Fisher's exact tests and independent sample t-tests were used, and significance was set at p < 0.05.

Results: Twenty-two studies were included, which reported on 168 GCTBs treated with orthovoltage and 393 treated with megavoltage RT. Transformation incidence was 14% (n = 24) for orthovoltage and 1.8% (n = 7) for megavoltage RT, an 8-fold difference (odds ratio (OR) 9.1, 95% confidence interval (CI) 3.9-22, p < 0.001). Mean time to transformation was 8.7 years for orthovoltage and 11.2 years for megavoltage RT (p=0.28). Incidence of local recurrence was 38% (63/167) for orthovoltage and 17% (66/393) for megavoltage RT (OR 3.3, 95% CI 2.0-4.6, p < 0.001).

Conclusions: The risk of developing a malignancy after RT of GCTB is 8 times lower with megavoltage than with orthovoltage. Malignant transformation with megavoltage, while not zero, is lower than that in historical series. Use of modern RT techniques in inoperable or refractory GCTB may be appropriate.

Abstract Image

Abstract Image

骨巨细胞瘤恶性转化的风险是正电压放疗的8倍。
背景:骨巨细胞瘤(gct)的一线治疗是手术;放疗(RT)是为不能手术或难治性病例保留的。虽然RT技术在过去的几十年里发生了巨大的变化,随着能量更高的兆瓦电压RT取代了正电压RT,但对RT后高恶性转化率的担忧限制了它的使用。有证据表明,与正电压放疗相比,巨电压放疗后继发恶性肿瘤的发生率较低,但尚未在gct中进行研究。我们的主要目的是比较正压和特压放疗治疗的GCTB恶性转化的发生率。方法:回顾文献,确定1900年1月至2019年12月期间报道RT治疗GCTBs的研究。未报道RT模式或单独的正电压和巨电压结果的研究被排除。纳入分析的是我们机构的6例患者。主要观察指标为恶性转化的发生率;次要结果为转化时间和局部复发率。采用Fisher精确检验和独立样本t检验,显著性设为p < 0.05。结果:纳入了22项研究,其中正压治疗168例gctb和特大电压RT治疗393例。正压治疗的转化发生率为14% (n = 24),特大电压RT治疗的转化发生率为1.8% (n = 7),差异为8倍(优势比(OR) 9.1, 95%可信区间(CI) 3.9-22, p < 0.001)。正压转换平均时间为8.7年,特压转换平均时间为11.2年(p=0.28)。正电压组局部复发率为38%(63/167),高压组局部复发率为17% (66/393)(OR 3.3, 95% CI 2.0 ~ 4.6, p < 0.001)。结论:巨电压治疗GCTB术后发生恶性肿瘤的风险比正电压治疗低8倍。巨电压时的恶性转化虽不为零,但低于历史序列。在不能手术或难治性GCTB中使用现代放射治疗技术可能是合适的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Sarcoma
Sarcoma Medicine-Radiology, Nuclear Medicine and Imaging
CiteScore
5.00
自引率
0.00%
发文量
15
审稿时长
14 weeks
期刊介绍: Sarcoma is dedicated to publishing papers covering all aspects of connective tissue oncology research. It brings together work from scientists and clinicians carrying out a broad range of research in this field, including the basic sciences, molecular biology and pathology and the clinical sciences of epidemiology, surgery, radiotherapy and chemotherapy. High-quality papers concerning the entire range of bone and soft tissue sarcomas in both adults and children, including Kaposi"s sarcoma, are published as well as preclinical and animal studies. This journal provides a central forum for the description of advances in diagnosis, assessment and treatment of this rarely seen, but often mismanaged, group of patients.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信